Expression of membrane inhibitor of reactive lysis in non-small cell lung carcinoma and its clinical significance
10.3760/cma.j.issn.1008-6706.2009.04.001
- VernacularTitle:膜反应性溶解抑制因子在非小细胞肺癌中的表达及其临床意义
- Author:
Weipeng ZHAO
;
Bo ZHU
;
Wei PENG
;
Yuzhong DUAN
;
Zhengtang CHEN
- Publication Type:Journal Article
- Keywords:
Antigens,CD59;
Cytotoxicity tests,immunologic;
Careinoma,non-small cell lung
- From:
Chinese Journal of Primary Medicine and Pharmacy
2009;16(4):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To survey membrane inhibitor of reactive lysis(MIRL) expression in non-small cell lung careinoma(NSCLC) and to analyze the relationship between MIRL expression and clinical staging, adjuvant chemotherapy and disease-free survial. Methods The expression of MIRL in 8 adjacent tissues and 36 NSCLC sam-pies were determined by immunohistochemistry. Furthermore, the relationship between MIRL expression and clinical stage ,adjuvant chemotherapy and disease-free survival was assayed by follow-up. Results Among 36 samples of non-small-cell lung cancer,there were 10(27.8%) samples expressing MIRE. Out of 18 samples of squamous carcinoma, 4(22.2%) expressed MIRL,while 6(37.5%) expressed it in 16 samples of adenocarcinoma,there was no statistical significance between them(P>0.05). There were no expression in 2 samples of large cell carcinoma. There was no correlation between MIRL expression and disease-free survival(P>0.05). MIRL positive expression rate in patients with preoperational adjuvant chemotherapy was significantly lower than that of those without preoperational adjuvant chemotherapy(P<0.05). Conclusions There is great percentage of MIRE expression in NSCLC. Our present study suggests that the immunological inhibition of MIRL should be blocked when monoclonal antibody is used in the treat-merit of NSCLC.
